Liquidia Corp has developed a proprietary inhaled formulation of treprostinil, YUTREPIA, approved by the FDA in May 2025 and currently driving commercial revenues alongside a generic treprostinil injection marketed with Sandoz. The company’s financials show substantial operating losses but improving trends as commercialization progresses. Future growth depends on manufacturing capacity expansions, ongoing clinical development of liposomal formulations, and navigating pricing and regulatory challenges amid cost-containment pressures. Despite improved cash flow from operations, net losses persist, underscoring the importance of capital management and operational execution over the near term.